Precision Medicine in Oncology®

Future Directions for Liquid Biopsy in NSCLC

Liquid Biopsy and Next-Generation Sequencing

Interpretation of NSCLC Plasma Genotyping Results

Liquid Biopsy: Differences Among Technologies

Latest Videos

PARP Inhibitors in Recurrent Ovarian Cancer

Secondary Debulking in Recurrent Ovarian Cancer

Bevacizumab in Recurrent Ovarian Cancer

Approaching Recurrent Ovarian Cancer

Biomarkers and Molecular Testing in Ovarian Cancer

I-O Therapy in Advanced Ovarian Cancer

Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

Bevacizumab in the Neoadjuvant Setting of EOC

Incorporating Bevacizumab into First-Line Practice for EOC

Upfront Bevacizumab in Advanced Ovarian Cancer

CME Content

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Jack W. Erter III, MD, MMHC; Geoffrey Ku, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Komal Jhaveri, MD, FACP; Ruta D. Rao, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Sunnie S. Kim, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Geoffrey Ku, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Tennessee Oncology Practice Society

1 Session is Available!

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Texas Society of Clinical Oncology

1 Session is Available!

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Daniela A. Bota, MD, PhD; Maya Hrachova, DO

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Amy E. Armstrong, MD; Anu Batra, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Daniela A. Bota, MD, PhD; Shiven Patel, MD, MBA

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Jack W. Erter III, MD, MMHC; Anne Chiang, MD, PhD

Washington State Medical Oncology Society

1 Session is Available!

In-Person + Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

December 4, 2026

Wyoming State Oncology Society

1 Session is Available!

Montana State Oncology Society

1 Session is Available!

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

In-Person + Virtual Event

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Washington State Medical Oncology Society

Mrinal M. Gounder, MD; Megan Jagosky, MD

Breast Cancer Symposia in San Antonio

December 7, 2026

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Iowa Oncology Society

Ravin Ratan, MD, M.Ed; Megan Jagosky, MD

Empire State Hematology & Oncology Society (New York)

2 Sessions are Available!

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

South Carolina Oncology Society

2 Sessions are Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Wisconsin Association of Hematology and Oncology

Neel Belani, MD; Eric K. Singhi, MD

In-Person + Virtual Event

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Neil M. Iyengar, MD; Ajit K. Bisen, MD, MBA

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

December 11, 2026

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Nevada Oncology Society

Mrinal M. Gounder, MD; Makenzi Evangelist, MD

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Northern California

Yana G. Najjar, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Erika P. Hamilton, MD; Katherine Sanchez, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | West Virginia Oncology Society

Priya Kumar, MBBS, MS; Christine L. Hann, MD, PhD

Nevada Oncology Society

1 Session is Available!

Louisiana Oncology Society

1 Session is Available!

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Missouri Oncology Society

1 Session is Available!

Cases and Conversations: Implementing Recent Updates to Improve Outcomes for Patients With MDS

December 18, 2026

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Jonathan Riess, MD, MS; Fawzi Abu Rous, MD; Julia Rotow, MD

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

(CPE Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD; Jonathan Strosberg, MD